Russell Burcombe - Concepedia

Author

Russell Burcombe

Also Known As

Hisham Hamed, R Burcombe, R J Burcombe, R. Burcombe, R. J. BURCOMBE, R. J. Burcombe, R.J Burcombe, R.J. Burcombe, Richard Simcock, Russell Burcombe

106

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Mount Vernon Hospital Luton and Dunstable Hospital Royal Marsden Hospital Institute of Cancer Research Royal Marsden NHS Foundation Trust

About

Russell Burcombe is an author at Mount Vernon Hospital specializing in health sciences, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	5	5	395
2	Medicine	4	4	329
3	Obstetrics	2	2	293
4	Pathology	2	2	190
5	Engineering	1	1	66

Russell Burcombe

Publications

899

Citations

H-Index

Page 1

	Year	Citations
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Mei-Lin W. Ah-See, Andreas Makris, N. Jane Taylor, Clinical Cancer Research	2008	262
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Russell Burcombe, Andreas Makris, P I Richman, British Journal of Cancer Surgical OncologyBreast OncologyMedicinePathologyGynecology	2004	176
Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual Russell Burcombe, Andreas Makris, M. Pittam, The Breast Surgical OncologyBreast OncologyHealth SciencesSexual Well-beingMedicine	2003	117
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer Russell Burcombe, George D. Wilson, Mitch Dowsett, Breast Cancer Research	2006	85
Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography Russell Burcombe, Andreas Makris, M. Pittam, European Journal of Cancer Breast OncologyEngineeringNeoadjuvant ChemotherapyMedical ImagingGood Clinical Response	2002	66
Subcutaneous Trastuzumab (Herceptin&lt;sup&gt;&#174;&lt;/sup&gt;): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer Russell Burcombe, Richard Simcock, Kunal Samanta, Advances in Breast Cancer Research	2013	59
Hyperhomocysteinemia in women with advanced breast cancer A. Gatt, Andreas Makris, Helen Cladd, International Journal of Laboratory Hematology	2007	43
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) Alistair Ring, Lucy Kilburn, Alex Pearson, Clinical Cancer Research	2023	30
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer M.A. Bergamino, Elena López‐Knowles, Gabriele Morani, EBioMedicine	2022	25
Pre-treatment Haemoglobin Levels and the Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Mark Beresford, Russell Burcombe, Mei-Lin Ah-See, Clinical Oncology Breast OncologyOncologyCancer ManagementHematologyBreast Cancer	2006	22

Page 1